

S/N 09/308,955
Attorney Docket No. PC9808A

5

Remarks

After entry of this amendment, claims 1, 4, 15-17, 19, 20, 22, and 23 are pending in the present application. Claims 4 and 22-23 were rejected under 35 U.S.C. 112, second paragraph. Claim 4 is amended as suggested by the Examiner, by adding "pain and inflammation" to replace subject matter lacking antecedent basis. Claims 22 and 23 depend from claim 4 and thus now depend from an allowable claim. This overcomes the only remaining rejection under 35 U.S.C. 112, second paragraph.


Applicants now believe that further and favorable action in the form of a Notice of Allowance is next in order, and such action is earnestly solicited.

No fee is believed to be due; however, the Commissioner is hereby authorized to charge any extension of time fee necessary to keep the application active given the current status as under final rejection, and any other fees that may be required, or credit any overpayment, to Deposit Account No. 16-1445.

20

Respectfully submitted,
Pfizer, Inc.

Date: January 26, 2004


Raymond D Thompson
Reg. No. 30,695

25

Pfizer, Inc.
Eastern Point Road, MS 8260-1611
Groton, CT 06340

30

Customer ID No.: 28523